Revelation Total Other Income Expense Net from 2010 to 2024

REVBW Stock  USD 0.01  0.0001  0.81%   
Revelation Biosciences Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Revelation Biosciences Total Other Income Expense Net regression line of quarterly data had r-squared of  0.35 and coefficient of variation of  263.86. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
8.5 M
Current Value
M
Quarterly Volatility
3.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Other Operating Expenses of 7 M, Total Operating Expenses of 7 M or Total Other Income Expense Net of 9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.54. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Check out the analysis of Revelation Biosciences Correlation against competitors.
For more information on how to buy Revelation Stock please use our How to Invest in Revelation Biosciences guide.

Latest Revelation Biosciences' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Revelation Biosciences over the last few years. It is Revelation Biosciences' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Revelation Total Other Income Expense Net Regression Statistics

Arithmetic Mean1,167,157
Coefficient Of Variation263.86
Mean Deviation2,022,044
Median2.00
Standard Deviation3,079,641
Sample Variance9.5T
Range9M
R-Value0.59
Mean Square Error6.6T
R-Squared0.35
Significance0.02
Slope407,206
Total Sum of Squares132.8T

Revelation Total Other Income Expense Net History

2024M
20238.5 M
202235 K
2021-36.4 K
2020 9084.0

About Revelation Biosciences Financial Statements

Revelation Biosciences investors use historical fundamental indicators, such as Revelation Biosciences' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net8.5 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revelation Stock Analysis

When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.